No common malignancy is as rapidly and inevitably fatal as pancreatic ductal
adenocarcinoma (PDA). This grim fact has driven substantial research efforts into this …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Pancreatic ductal adenocarcinoma (PDA) is the 12th most common cancer in the United
States. As of January 7, 2016, the American Cancer Society reported that pancreatic cancer …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer,
with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of …

Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid
tumours and poses an unsolved problem in cancer medicine. Despite the recent success of …

Introduction: Prognosis remains dismal for pancreatic ductal adenocarcinoma (PDAC).
Genomics and proteomics have depicted heterogeneity in PDAC. Collectively, this …

Pancreatic ductal adenocarcinoma (PDA) remains a devastating disease with nearly equal
incidence and mortality rates. Over the past few decades, a litany of randomized clinical …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality,
despite significant improvements in diagnostic imaging and operative mortality rates. The 5 …

Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with
an overall 5-year survival rate of less than 4%. On the molecular level, an increasing number …